OTHER INFORMATION
+Added: Master Development and License Agreement for Products Between Elite Pharmaceuticals, Inc.
+Added: and Mikah Pharma LLC, effective as of June 10, 2021.(Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)).*
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
12 unchanged sentences
Furnished herewith.
−Removed: Pursuant to the requirements
−Removed: of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
−Removed: thereunto duly authorized.
+Added: Pursuant to the requirements of
+Added: the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
+Added: duly authorized.
ELITE PHARMACEUTICALS, INC.
−Removed: February 16, 2021
+Added: August 16, 2021
/s/ Nasrat Hakim
2 unchanged sentences
(Principal Executive Officer)
−Removed: February 16, 2021
−Removed: /s/ Carter J.
−Removed: Chief Financial Officer, Treasurer and
+Added: August 16, 2021
+Added: /s/ Marc Bregman
+Added: Chief Financial Officer, Treasurer and Secretary
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.